TT 12

Drug Profile

TT 12

Alternative Names: HP-VST - Tessa Therapeutics; Human papillomavirus specific T cells - Tessa Therapeutics; TT12; TT12-HP VST

Latest Information Update: 11 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baylor College of Medicine
  • Developer Baylor College of Medicine; Tessa Therapeutics
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Immunomodulators; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cervical cancer; Oropharyngeal cancer

Most Recent Events

  • 11 Apr 2018 Tessa Therapeutics plans a phase II trial for Cancer in 2019
  • 30 Sep 2015 Phase-I clinical trials in Cervical cancer in USA (IV)
  • 30 Sep 2015 Phase-I clinical trials in Oropharyngeal cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top